Press Releases Agenus Inc.

Equities

AGEN

US00847G8042

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
11.69 ^USD	+40.84%		+120.15%	-29.40%

Apr. 12	Sector Update: Health Care Stocks Slipping Late Afternoon	MT
Apr. 12	Sector Update: Health Care	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Agenus Inc. - Botensilimab, Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting	Apr. 25	AQ
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting	Apr. 24	BU
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update	Apr. 23	BU
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	Apr. 15	AQ
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	Apr. 12	BU
Agenus Announces Reverse Stock Split of Common Stock	Apr. 05	BU
Agenus : Submission of Matters to a Vote of Security Holders - Form 8-K	Apr. 05	PU
Agenus: Q4 Earnings Snapshot	Mar. 14	AQ
Agenus Reports Fourth Quarter and Full Year 2023 Results	Mar. 14	BU
Agenus Announces Preclinical Data on BMS-986442 at AACR 2024	Mar. 07	AQ
Agenus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	Mar. 06	AQ
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024	Mar. 06	BU
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 05	BU
Agenus to Provide Corporate Update and Fourth Quarter and Full Year 2023 Financial Report	Mar. 01	AQ
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report	Feb. 29	BU
Agenus to Participate in Leerink Partners Global Biopharma Conference	Feb. 26	BU
Healthcare Innovations and Collaborations Fuel Industry Expansion Stocks Under $1 Look Now! OCGN, VTAK, RSCI, VERU, AGEN	Feb. 21	AQ
Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design	Feb. 15	PR
GSK's RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk \| GSK	Feb. 06	AQ
GSK's regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration \| GSK	Feb. 06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Agenus Inc.

Equities

AGEN

US00847G8042

Press Releases

Filters